Option chain shows key data for Plus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Plus Therapeutics.

Plus Therapeutics (NASDAQ:PSTV) Stock, Option Chain

PLUS THERAPEUTICS INC

Plus Therapeutics

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Stock Movers

News

Intraday Update

Markets

Movers

Trading Ideas

ALUR

AUID

BHAT

BNTC

GCTK

INNV

MCVT

OUST

PNBK

PSTV

RVSB

TNMG

USAR

XHLD

Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

eye-5248678

Plus Therapeutics shares are trading higher by 183% during Thursday&#39;s session. The company announced that the FDA accepted the name REYOBIQ for the company&#39;s lead asset.

Why Plus Therapeutics (PSTV) Shares Are Exploding Higher

movers image

ABLV

ADVB

ATCH

CKPT

EXOD

HOOD

ICON

KZIA

LUNR

MLYS

NPWR

SNOA

STBX

STSS

SUNE

TRVI

VEEE

Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

Health Care

Press Releases

General

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Financing

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Offerings

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Earnings

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Ainos

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Mainz Biomed

Ocean Biomedical

PharmaCyte Biotech

Portage Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

HC Wainwright & Co.

D. Boral Capital

Ascendiant Capital

Maxim Group

JonesTrading

Screenshot 2024-03-29 at 1.10.09 AM

Biotech

This Biotech Is Creating Targeted Radiotherapuetics For Some Of The Deadliest Cancers

Comments

Plus Therapeutics

Plus Therapeutics (PSTV) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga